Jump to full article: China Daily (cn), 2009-08-10
Author: Zhou Yan (China Daily
Intro: the world's largest pharmaceutical company is also busy expanding its presence in China to capitalize on the country's growing role in the world's pharmaceutical market.
. . .
To tap into the anti-smoking market, Pfizer launched its smoking-cessation Champix product in late 2008.
Pfizer is not the only pharmaceutical maker to recognize the market potential in stop-smoking pills.
Its rivals, Swiss drug maker Novartis AG and US-based Johnson & Johnson, also introduced their quit-smoking products.
Novartis introduced Nicotineel to China in 2008, and Johnson & Johnnson introduced Nicorette to China this year.
It's estimated by Novartis that the smoking cessation market in China is valued at around 30 billion yuan.
"It's still early to comment on the outcome of Champix, but as far as I know, we don't have anything as good as Champix in the smoking cessation area so far, " Mackay said about his company's product.
Jump to full article » |